Latest News
Open Book Extracts Acquires Chilmark Labs
Tuesday 16 June 2020

US-based cannabinoid products processor Open Book Extracts has signed definitive agreements to acquire Chilmark Labs and its Israeli affiliate, Beetlebung Pharma Ltd., the company said.

Open Book said the deal will bring a leadership position in the manufacturing of high-purity rare and minor cannabinoids.

Together, the merged companies will bring to market commercial-scale production of precise, consistently formulated custom cannabinoid blends, and spearhead research and development into the efficacy of custom formulations to deliver targeted therapeutic outcomes.

With research and production facilities located in Israel and the United States, Chilmark Labs has developed proven methods to efficiently manufacture rare cannabinoids from hemp and citrus, including CBN, CBC, THCV, and CBDV.

By making these previously unattainable rare cannabinoids more accessible, Chilmark Labs is unlocking new therapeutic possibilities and developing formulations to maximize the nutraceutical and pharmacological properties of rare cannabinoids.

Dr. Salzman joins Open Book Extracts as its chief science officer. Dr. Salzman grew up in Massachusetts, graduating from Yale College and Harvard Medical School, followed by a residency at Columbia University and postdoctoral fellowships at Beth Israel and Mass General.

He went on to establish and lead the Division of Critical Care Medicine at Children's Hospital Medical Center in Cincinnati, Ohio, and then turned to entrepreneurship with a series of successful drug discoveries. He has strong research relationships with universities in Israel and the United States and will lead Open Book Extracts' medical advisory board.

Upon coupling Open Book Extracts' commercial-scale production capabilities and cGMP-certified facility with Chilmark Labs' proficiency in rare cannabinoid isolation and novel cannabinoid development, the combined companies plan to invest heavily in scaled production and R and D to serve their global distribution channels.

Chilmark Labs manufactures and produces rare cannabinoids at a purity exceeding 99%, with research and production facilities located in Israel, Australia and the United States, and with a scientific staff of Ph.D. chemists and engineers pioneering research and development in rare cannabinoid manufacturing.

The company leads the development of proprietary GMP-compliant release and stability methods utilising ultra-high performance liquid chromatographic methods for CBN, CBC, THCV, and CBDV.

Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP certified, vertically integrated grower, processor and manufacturer of premium plant-based products.

The organisation's ownership of the entire supply chain, a state-of-the-art extraction campus, product development and manufacturing capabilities, and aggregation of experienced professionals from relevant industries support its efforts to bring transparency and high-quality ingredients to the new hemp extracts market.
Date Published: 16/06/2020